These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 36186882)

  • 21. Pre-treatment Pain Symptoms Influence Antidepressant Response to Ketamine in Depressive Patients.
    Lan X; Zhou Y; Wang C; Li W; Zhang F; Liu H; Fu L; Wu K; McIntyre RS; Ning Y
    Front Psychiatry; 2022; 13():793677. PubMed ID: 35370832
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Electrophysiological correlates and predictors of the antidepressant response to repeated ketamine infusions in treatment-resistant depression.
    de la Salle S; Phillips JL; Blier P; Knott V
    Prog Neuropsychopharmacol Biol Psychiatry; 2022 Apr; 115():110507. PubMed ID: 34971723
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
    Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
    J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
    Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
    J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intravenous Ketamine Infusions in Treatment-Resistant Bipolar Depression: An Open-Label Naturalistic Observational Study.
    Wilkowska A; Włodarczyk A; Gałuszko-Węgielnik M; Wiglusz MS; Cubała WJ
    Neuropsychiatr Dis Treat; 2021; 17():2637-2646. PubMed ID: 34421299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
    Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
    Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of plasma VEGF levels and the antidepressant effects of ketamine in patients with depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Zhang B; Zhou SM; Yan S; Yang MZ; Nie S; Ning YP
    Ther Adv Psychopharmacol; 2021; 11():20451253211014320. PubMed ID: 34035893
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ketamine and other glutamate receptor modulators for depression in bipolar disorder in adults.
    McCloud TL; Caddy C; Jochim J; Rendell JM; Diamond PR; Shuttleworth C; Brett D; Amit BH; McShane R; Hamadi L; Hawton K; Cipriani A
    Cochrane Database Syst Rev; 2015 Sep; (9):CD011611. PubMed ID: 26415966
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Plasma BDNF concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression.
    Zheng W; Zhou YL; Wang CY; Lan XF; Zhang B; Zhou SM; Yan S; Ning YP
    PeerJ; 2021; 9():e10989. PubMed ID: 33850645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
    Phillips JL; Jaworska N; Kamler E; Bhat V; Blier J; Foster JA; Hassel S; Ho K; McMurray L; Milev R; Moazamigoudarzi Z; Placenza FM; Richard-Devantoy S; Rotzinger S; Turecki G; Vazquez GH; Kennedy SH; Blier P;
    BMC Psychiatry; 2020 Jun; 20(1):268. PubMed ID: 32487236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurocognitive performance of repeated versus single intravenous subanesthetic ketamine in treatment resistant depression.
    Shiroma PR; Thuras P; Wels J; Albott CS; Erbes C; Tye S; Lim KO
    J Affect Disord; 2020 Dec; 277():470-477. PubMed ID: 32871534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can 'floating' predict treatment response to ketamine? Data from three randomized trials of individuals with treatment-resistant depression.
    Acevedo-Diaz EE; Cavanaugh GW; Greenstein D; Kraus C; Kadriu B; Park L; Zarate CA
    J Psychiatr Res; 2020 Nov; 130():280-285. PubMed ID: 32861983
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.
    Pennybaker SJ; Niciu MJ; Luckenbaugh DA; Zarate CA
    J Affect Disord; 2017 Jan; 208():560-566. PubMed ID: 27839782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid effectiveness of intravenous ketamine for ultraresistant depression in a clinical setting and evidence for baseline anhedonia and bipolarity as clinical predictors of effectiveness.
    Thomas RK; Baker G; Lind J; Dursun S
    J Psychopharmacol; 2018 Oct; 32(10):1110-1117. PubMed ID: 30182797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression.
    Delfino RS; Del-Porto JA; Surjan J; Magalhães E; Sant LCD; Lucchese AC; Tuena MA; Nakahira C; Fava VAR; Steglich MS; Barbosa MG; Sarin LM; Lacerda ALT
    J Affect Disord; 2021 Jan; 278():515-518. PubMed ID: 33017679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between plasma levels of BDNF and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation.
    Zheng W; Zhou YL; Wang CY; Lan XF; Zhang B; Zhou SM; Yan S; Yang MZ; Nie S; Ning YP
    Ther Adv Psychopharmacol; 2020; 10():2045125320973794. PubMed ID: 33282177
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression.
    Lally N; Nugent AC; Luckenbaugh DA; Ameli R; Roiser JP; Zarate CA
    Transl Psychiatry; 2014 Oct; 4(10):e469. PubMed ID: 25313512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular effects of repeated subanaesthetic ketamine infusion in depression.
    Zhou YL; Liu WJ; Wang CY; Zheng W; Lan XF; Weng SY; Ning YP
    J Psychopharmacol; 2021 Feb; 35(2):159-167. PubMed ID: 32720857
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A single infusion of ketamine improves depression scores in patients with anxious bipolar depression.
    Ionescu DF; Luckenbaugh DA; Niciu MJ; Richards EM; Zarate CA
    Bipolar Disord; 2015 Jun; 17(4):438-43. PubMed ID: 25400146
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.